A Next-Gen Candidate Built for Better Outcomes. SureNano Science is developing GEP-44 as a patented next-generation metabolic therapy designed to address the limitations of first-generation GLP-1 drugs, positioning this...
Over the forecast period of 2026-2030, the market is projected to grow at a CAGR of 20%.Secondary Source Chapter 2. Oral GLP-1 & Small-Molecule Obesity Therapies Market Executive Summary 2.1. Market Size & Forecast (2026 2030) ($M/$Bn) 2.2.
High-Resolution Metabolic Phenotyping for Next-Generation Obesity Therapies. Track how drugs change whole-body energy use across the full circadian cycle. See how treatments shift substrate uses toward lipid oxidation or glucose.
Eli Lilly's obesity therapies, anchored by its GLP-1 innovations and manufacturing prowess, are poised to reshape both global health outcomes and industry dynamics.
Could it be that GLP-1 agonism is only the beginning, not the end of the story of a renaissance in obesity medicine? Richard DiMarchi, Matthias Tschp, and a number of their colleagues seem to think so.
As we can see from the illustration, Glp-1 And Next-Generation Obesity Therapies 2026-2030 A has many fascinating aspects to explore.
The global obesity crisis is escalating, with the WHO predicting over 1 billion cases by 2030. GLP-1 agonists like Ozempic and Mounjaro are transforming the treatment landscape for type 2 diabetes and obesity, with significant market growth expected.
Kiefer Mespelt, DO. Now is the time for pulmonary clinicians to become comfortable counseling patients about and treating obesity. By 2030, half of the US population will have obesity, a quarter of which will be severe (Ward et al. NEJM. 2019;2440-2450).
